RATIONALE: Currently, 1% of children in the US have a peanut allergy. With no existing cure for peanut allergy, treatments that inhibit allergic effector cell activation and degranulation may prove useful in preventing reactions. CD300c is an activating receptor known to cross-react with inhibitory receptor and family member CD300a. Engagement of CD300a has been shown to halt degranulation of mast cells. We are interested in utilizing CD300c in peanut allergy to determine its ability in inhibiting allergic effector cell degranulation. METHODS: Peanut allergy was confirmed in 10 subjects by specific-IgE > 10 kU/L and a positive double-blind, placebo-controlled, food challenge. Peanut allergic plasma from these subjects was used to sensitize Rat Basophilic Leukemia SX-38 cells in the presence or absence of antiCD300c antibody at varying concentrations. Degranulation was then measured by beta-hexosaminidase release following peanut antigen stimulation of the cells. RESULTS: We showed clear and consistent trends in inhibition of mast cell degranulation by use of anti-CD300c. We reached an average percent inhibition of 22.17% after treatment with anti-CD300c at low concentrations. Low concentrations of anti-CD300c showed greater inhibition of beta-hexosaminidase release when compared with higher concentrations of anti-CD300c. CONCLUSIONS: Anti-CD300c antibodies at low concentrations have the ability to decrease degranulation of mast cells sensitized to peanut. This indicates that cross-reaction with CD300a may be occurring at lower concentrations, leading to decreased cellular degranulation. Further studies will elucidate the roles of other CD300 family members in mast cell inhibition and activation. Novartis, Inc., East Hanover, NJ. RATIONALE: Allergic rhinitis triggered by cedar pollen is referred to as cedar pollinosis (CP) in Japan. CP affects about 30% of Japan's population, and about 25% of patients report refractory symptoms. Anti-IgE therapy (omalizumab) interrupts the allergic cascade. Efficacy of omalizumab added to anti-histamines and nasal corticosteroids was evaluated for severe CP. METHODS: Symptomatic, severe cedar sensitized adolescent and adult patients from Tokyo and surrounding areas were enrolled in a 12-week double blinded, placebo controlled, randomized parallel treatment study within the 2018 cedar pollen season. Patients were randomized in a 1:1 ratio to receive omalizumab or placebo according to the dosing table. Primary endpoint was mean nasal symptom score (within the severe symptom period). Secondary endpoints included mean ocular symptom score and medication score. RESULTS: 336 Japanese patients received omalizumab (n 5 161) or placebo (n 5 175), and approximately 98% completed the treatment period. Baseline characteristics were similar between treatment groups. Differences in LS mean for nasal and ocular symptom scores between omalizumab and placebo groups were 21.03 (95% confidence interval [CI]: 21.44 to 20.62, p<0.001) and -0.87 (95% CI: 21.18 to 20.55, p<0.001), respectively. Magnitude of nasal symptom improvement was clinically relevant (prespecified clinically relevant difference was 0.87). Omalizumab reduced mean nasal and ocular symptom medication scores (LS mean differences were -1.10 and -0.95, respectively). No unexpected safety signals were identified. CONCLUSIONS: In severe Japanese CP patients, omalizumab added to standard treatment reduced symptoms. Omalizumab is a well-tolerated, mechanistically targeted therapy and represents a clear advance for these patients.
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